Rheumatology

Breast Cancer, Non-metastatic

Questions discussed in this category

Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

1 Answer available

Do you offer adjuvant radiation therapy for a breast cancer patient with dermatomyositis?

If so, what dose-fractionation do you utilize? What other factors do you take into consideration?

2 Answers available

Can you continue checkpoint inhibitor therapy in the setting of severe cutaneous irAE while concurrently treating the cutaneous reaction?

2 Answers available

How would you approach evaluation and treatment of a patient on pembrolizumab therapy who presents with symmetric, proximal, upper extremity and lower extremity painful weakness without an elevated CK?

1 Answer available

Papers discussed in this category

J Immunother Cancer,

Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.

Rheumatology

Breast Cancer, Non-metastatic

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology